Analysts Set Celldex Therapeutics, Inc. (NASDAQ:CLDX) Price Target at $44.50

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been assigned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, eight have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $44.4545.

CLDX has been the topic of a number of analyst reports. The Goldman Sachs Group upped their price target on Celldex Therapeutics from $30.00 to $34.00 and gave the company a “neutral” rating in a research report on Monday, March 2nd. Barclays lifted their price objective on Celldex Therapeutics from $21.00 to $24.00 and gave the stock an “underweight” rating in a research note on Wednesday, December 17th. Stifel Nicolaus reiterated a “buy” rating and issued a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a report on Thursday, February 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. Finally, Wolfe Research upgraded shares of Celldex Therapeutics from a “peer perform” rating to an “outperform” rating and set a $44.00 price target for the company in a report on Monday.

Celldex Therapeutics Trading Up 1.6%

Shares of CLDX stock opened at $31.68 on Monday. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -8.14 and a beta of 1.17. The business’s 50-day moving average price is $26.98 and its 200-day moving average price is $26.43. Celldex Therapeutics has a 12 month low of $14.40 and a 12 month high of $34.52.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The business had revenue of $0.12 million for the quarter, compared to the consensus estimate of $1.53 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 41.67%. On average, sell-side analysts predict that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

Institutional Trading of Celldex Therapeutics

A number of institutional investors have recently bought and sold shares of CLDX. Aster Capital Management DIFC Ltd acquired a new stake in Celldex Therapeutics during the third quarter worth approximately $26,000. Wilmington Savings Fund Society FSB bought a new position in shares of Celldex Therapeutics during the 3rd quarter worth approximately $42,000. Russell Investments Group Ltd. boosted its holdings in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Celldex Therapeutics during the 3rd quarter worth approximately $63,000. Finally, Strs Ohio acquired a new stake in shares of Celldex Therapeutics during the 3rd quarter worth approximately $75,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.